Cross-Border Impact Ventures

🌟 Farewell and Thank You to Our Amazing Intrapreneurs! 🌟 Cross-Border Impact Ventures is saying farewell to our incredible Intrapreneurs from the Venture for Canada Intrapreneurship Program. We want to take a moment to express our gratitude for their outstanding contributions over the past few months: Quratulain Ahsan Khan: Currently double-majoring in Biology and Psychology at York University. Thank you for your contributions to our ESG strategy, Quratulain! Hari Patel: A first-year Bachelor of Business Administration (BBA) student specializing in Finance at the Schulich School of Business. Thank you for your invaluable work on our Investment team, Hari! Harikrishna Patel: A fourth-year student currently pursuing a Bachelor of Business Administration (BBA) at the Schulich School of Business. Harikrishna's research and data management support on our Investor Relations team was extremely helpful in the midst of gearing up for our next fundraise. Thank you, Harikrishna! We are grateful to Venture for Canada and their Intrapreneurship Program for connecting us with such exceptional talent. We wish all of our Intrapreneurs the best of luck with the rest of their university journeys!

Donna Parr will be at the 2025 Entrepreneur & Investor Life Sciences Summit to speak on the Venture Capital: The Fuel for Life Sciences Growth panel. We look forward to connecting with the impressive line-up of distinguished speakers, national and local investors, and numerous Utah life sciences startups that the Summit has to offer! #2025e&isummit

Cross-Border Impact Ventures has been selected to the ImpactAssets 50 2025 as an Emerging Impact Manager for the 5th year in a row! We’re proud to be selected among a diverse group of impact investment fund managers demonstrating the potential to create positive impact: http://bit.ly/IA502025 #IA50 #IA50EIM

On this International Women’s Day, we recognize the urgent need to close the gender gap in health outcomes—and celebrate the people working to make that a reality. At Cross-Border Impact Ventures, we are committed to closing these gaps by backing visionary companies that are transforming the landscape of women’s health.   Today, we want to highlight some of the incredible companies in our portfolio that are leading the charge in advancing gender equity in health:   Pendulum Systems uses artificial intelligence and machine learning to forecast healthcare demand to reduce wastage and stockouts of essential medicine and healthcare supplies.   Daye is a gynecological care provider focused on novel digital and physical products and diagnostics with the aim of eliminating the pain, shame, and inconvenience that is pervasive in care-seeking experiences for gynae health.   mOm Incubators has developed an affordable, collapsible, lightweight incubator that provides thermoregulation for newborns in order to prevent unnecessary NICU admissions, as well as providing care for babies in fragile contexts, ensuring consistent care and enabling safe relocation when necessary.   OncoLens is a digital health platform solving major and growing pain points in cancer care delivery by providing innovative oncology care management solutions to cancer patients and healthcare providers.   Sonio (exited) has developed an AI-enabled software company aiming to empower fetal ultrasound practitioners, bringing real time access to expert knowledge, improving security and quality on ultrasound exams, simplifying workflows and improving productivity.   Raydiant Oximetry, Inc. is addressing multiple unmet needs in maternal-fetal medicine, particularly emergency C-sections, newborn injury, and postpartum hemorrhage (PPH).   Axena Health is improving access and affordability to at-home pelvic floor disorder treatment for women through the Leva® Pelvic Health System.   Oxford Cancer Analytics has developed minimally invasive liquid biopsy tests that are affordable and scalable in any diagnostic facility worldwide so that early cancer detection tests can be accessed by those who need it the most.   Cardiosense is combining non-invasive physiological sensors and artificial intelligence for the detection, prediction, and management of cardiovascular disease.   We are so proud to support these companies as they do this important work towards a future where access, innovation, and equity in healthcare are no longer barriers for women and children to access quality healthcare. To all the entrepreneurs, funders, investors, researchers, and advocates working tirelessly to close the women’s health gap—thank you. Your work is driving impact, and we are honored to stand with you in this mission.   #IWD2025 #WomensHealth #ImpactInvesting 

In honor of Heart Awareness Month and International Women's Day, Cross-Border Impact Ventures is proud to welcome the 9th company to our portfolio, Cardiosense! Cardiosense is combining non-invasive physiological sensors and artificial intelligence for the detection, prediction, and management of cardiovascular disease. The company’s first product is called CardioTag, a wearable multi-sensor device, that together with its SenseHF algorithm, can noninvasively measure pulmonary capillary wedge pressure (PCWP), a leading indicator of escalating congestive heart failure and decompensation. Future use cases of CardioTag can be extended to preeclampsia and arterial blood pressure. We see that Cardiosense can have a huge impact for women's health globally and here is why: - Heart disease is the #1 killer of women - A subpopulation of heart failure called HFpEF disproportionately impacts women - Peripartum cardiomyopathy (heart failure postpartum) directly impacts women - Women who experience premature menopause (before age 40) have a significantly higher risk of developing heart failure and atrial fibrillation - Preeclampsia affects about 2-8% of pregnancies worldwide and is a leading cause of maternal and infant morbidity and mortality. Black women are at a higher risk of developing preeclampsia. We are thrilled to work with Amit Gupta (CEO, Co-founder), Omer Inan (CSO, Co-founder) and the entire Cardiosense team and partner with such a strong syndicate of investors including Hatteras Venture Partners, Broadview Ventures Inc, Laerdal Million Lives Fund, and OSF Ventures among others. Such a huge win for women's cardiovascular health! #cardiosense #womenshealth #Healthtech #heartawareness #heartmonth

Cross-Border Impact Ventures is proud to welcome Oxford Cancer Analytics (OXcan) to our portfolio! OXcan has developed minimally invasive liquid biopsy tests that are affordable and scalable in any diagnostic facility worldwide. Why does this matter? OXcan's first product targets lung cancer, one of the deadliest cancers in women. Since lung cancer is typically asymptomatic until late stage, women can (and usually do) live with lung cancer for several years before it becomes apparent, even for non-smoking women, who represent 15-20% of lung cancer cases. Survival rates for lung cancer decrease significantly with advanced stages of diagnosis (stage 3 and 4), which is why early detection is crucial. OXcan's platform has demonstrated remarkable cancer detecting sensitivity for early stage lung cancer. This is a truly exciting development in the field of cancer diagnostics, and CBIV is proud to be investing in a company that has enormous potential to reduce mortality and the cost of cancer treatment for people worldwide. We extend our sincerest congratulations to Peter Jianrui Liu, Andreas Halner and the entire OXcan team for closing their $11M Series A round. We are very proud to co-lead this round alongside We Venture Capital and co-investors that include Eka Ventures, Civilization Ventures, DigitalDx Ventures, Macmillan Cancer Support, Aurelium Ventures and OKG Capital. We look forward to this exciting journey together, and supporting OXcan in bringing early cancer detection tests to those that need it the most! #OXcan #WomensHealth #HealthTech #CancerCare #VentureCapital 

✨ Impact and ESG News ✨ Cross-Border Impact Ventures is proud to receive a Platinum rating for its first Fund, the Women's and Children's Health Technology Fund, as a result of BlueMark's Fund ID verification process. Cross-Border Impact Ventures engaged BlueMark to independently assess the alignment of our fund with impact investing and ESG best practices. Our fund’s impact approach was assessed across four key pillars of impact accountability: strategy, governance, management and reporting. The Platinum rating is the highest Fund ID recognition that can be awarded, and funds receiving a Platinum rating consistently employ leading practices and align with industry standards across the four assessment pillars. Thank you, BlueMark!

We are thrilled to share that Cross-Border Impact Ventures was nominated in the category of "Best Incubators, Accelerators, and Equity" at the Prix Galien USA Awards 2024! While we didn’t take home the award, it was the greatest honour to be nominated for an award that others have referred to as the Nobel Prize for the life sciences community. A special highlight was bringing along our friends Valentina Milanova 🇺🇦 of Daye and Anju Mathew of OncoLens. A huge congratulations to all the nominees in our category, and a well-deserved shoutout to Texas Medical Center Innovation Factory for taking home the award! #PrixGalien #GalienFoundation #healthcareinnovation

For Annie Theriault, speaking at and attending the 2024 #FemtechCanadaForum was a powerful reminder of how women’s healthcare, affecting 50% of the global population, remains under-researched, under-funded and under-served. Under the theme “Canada’s Path to Global Femtech Leadership,” this invite-only event explored the industry’s potential within the $1 trillion global women’s health technology market, showcasing Canada’s strategic influence and innovation. Cross-Border Impact Ventures is proud to be an impact investment firm in this incredibly exciting and important space. ✨Thank you to Femtech Canada, Sun Life, BDC, Centech Mtl, Cap Inclusive, Innovation Factory and everyone who made this event a memorable one. 👉To get involved with future opportunities like these, visit Femtech Canada’s website: https://lnkd.in/gDH_fbpW #Femtech #WomensHealth #Innovation #LifeSciences #Canada

Congratulations to Neil Ray, Russ DeLonzor and the Raydiant Oximetry, Inc. team! What an accomplishment!